

APC application front sheet – to accompany all applications to the APC

Title of paper:	Addition of Xaggitin XL® (Methylphenidate) to Surrey PAD as a brand option for prescribing		
Meeting date:	April 2023		
Agenda item:		Attachment(s):	
Author and contributors:	Multidisciplinary group from SH ICB and SABP NHS Trust. Comments to Alison Marshall (alison.marshall@sabp.nhs.uk)		
Paper type			
For:	APC members		

Executive Summary:

Currently the following recommendation is included on the Surrey PAD: *The preferred brands for 18mg, 27mg, 36mg and 54 mg modified release strengths are DelmosartXL® & Xenidate XL® and they will be considered AMBER shared care on the traffic light system.*

Other brands Matoride XL®, Xaggitin XL®, and Concerta XL® will not be BLACK listed on the traffic light system but it is anticipated that these brands will not be initiated by Surrey & Borders Partnership NHS Foundation Trust moving forwards.

This is now a request to include XaggitinXL® alongside DelmosartXL® and Xenidate XL® as a branded generic product as an alternative to Concerta® tablets.

As an example, Concerta® 18mg x 30 - £31.19; Xaggitin® 18mg x 30 - £15.59

Concerta® 54mg x 30 - £73.62; Xaggitin® 54mg x 30 - £36.80

The pharmacokinetic data (<https://surreyccq.res-systems.net/PAD//Content/Documents/2/APPENDIX%2014%20Methylphenidate-March-2018-revised.pdf>) provides support for the pharmacokinetic equivalence between XaggitinXL® and ConcertaXL®

This switch is supported by SABP NHS Trust, and considering data available via Open Prescribing ([link](#)) anticipated savings could exceed £20,000 per month.

Supporting letters are available for prescribers and families (attached).

It is suggested that the switch from ConcertaXL® can be undertaken in primary care but ideally switches should be undertaken with direct contact with patients. Communications should be done according to individual patient requirements.

- Due to recent stock shortages of methylphenidate products with this particular release profile, including XaggitinXL® as an alternative brand to be prescribed within Surrey Heartlands will provide a wider choice of bioequivalent products for clinicians to prescribe, and reduce the risk of disruption to treatment should the shortages recur.

- It should be noted that methylphenidate MR is a medicine specifically named in the guidance published by the Specialist Pharmacy Services as a product that should be prescribed by brand name - NHS Specialist Pharmacy Service – Which medicines should be considered for brand-name prescribing in primary care?

https://www.sps.nhs.uk/wp-content/uploads/2017/12/UKMi_QA_Brand-name_prescribing_Update_Nov2017.pdf

Relevant NICE guidance:

Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline

[NG87]Published: 14 March 2018 Last updated: 13 September 2019.

<https://www.nice.org.uk/guidance/ng87>

Actions for the APC:

1. The APC is asked to approve this addition to the brands of methylphenidate that may be prescribed within Surrey Heartlands ICB, so that the information can be uploaded to the PAD and also shared with primary and secondary care colleagues through other communication channels

Accompanying papers:

- Communication letters for parents/carers and for clinicians